Correlation of Lyso-Gb3 levels in dried blood spots and sera from patients with classic and Later-Onset Fabry disease

被引:54
作者
Nowak, Albina [1 ]
Mechtler, Thomas [2 ]
Kasper, David C. [2 ]
Desnick, Robert J. [3 ]
机构
[1] Univ Zurich, Univ Hosp Zurich, Dept Internal Med, Ramistr 100, CH-8091 Zurich, Switzerland
[2] ARCHIMED Life Sci, Leberstr 20, A-1110 Vienna, Austria
[3] Icahn Sch Med Mt Sinai, Dept Genet & Genom Sci, New York, NY 10029 USA
关键词
Lyso-Gb3; Dried blood spots (DBS); Fabry disease; alpha-Galactosidase A; ENZYME REPLACEMENT THERAPY; ALPHA-GALACTOSIDASE; AGALSIDASE-BETA; GLOBOTRIAOSYLSPHINGOSINE; PLASMA; MUTATIONS; DIAGNOSIS; VARIANT;
D O I
10.1016/j.ymgme.2017.06.006
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Fabry disease (FD), an X-linked lysosomal storage disorder, results from the deficient activity of alpha-galactosidase A (a-Gal A) and the accumulation of its substrates, globotriaosylceramide (Gb3) and its deacylated derivative, globotriaosyl-sphingosine (Lyso-Gb3). Here, we compared the levels of Lyso-Gb3 in dried blood spots (DBS) and sera in affected males and heterozygotes with the "Classic" and "Later-Onset" phenotypes. Methods: The Lyso-Gb3 concentrations in DBS and sera from 56 FD patients were determined by highly sensitive electrospray ionization liquid chromatography tandem mass spectrometry. Results: The serum Lyso-Gb3 levels in 18 and 5 affected males with the Classic and Later-Onset phenotypes, were 61 +/- 38 and 14 +/- 12 ng/mL, respectively. Lyso-Gb3 levels in 30 females from Classic families and three females from Later-Onset families were 10 +/- 5.4 and 2.4 +/- 1.0 ng/mL, respectively. The linear regression model with serum Lyso-Gb3 as the dependent variable and DBS Lyso-Gb3 an independent variable was described by the function y = -1.83 + 1.68 * x and showed a high coefficient of determination, R-2 = 0.976. T Conclusion: DBS provides a convenient, sensitive, and reproducible source to measure Lyso-Gb3 levels for diagnosis, initial phenotypic assignment, and therapeutic monitoring in patients with Fabry disease. (C) 2017 Elsevier Inc. All rights reserved.
引用
收藏
页码:320 / 324
页数:5
相关论文
共 31 条
  • [11] Ten-year outcome of enzyme replacement therapy with agalsidase beta in patients with Fabry disease
    Germain, Dominique P.
    Charrow, Joel
    Desnick, Robert J.
    Guffon, Nathalie
    Kempf, Judy
    Lachmann, Robin H.
    Lemay, Roberta
    Linthorst, Gabor E.
    Packman, Seymour
    Scott, C. Ronald
    Waldek, Stephen
    Warnock, David G.
    Weinreb, Neal J.
    Wilcox, William R.
    [J]. JOURNAL OF MEDICAL GENETICS, 2015, 52 (05) : 353 - 358
  • [12] Quantification of Globotriaosylsphingosine in Plasma and Urine of Fabry Patients by Stable Isotope Ultraperformance Liquid Chromatography-Tandem Mass Spectrometry
    Gold, Henrik
    Mirzaian, Mina
    Dekker, Nick
    Ferraz, Maria Joao
    Lugtenburg, Johan
    Codee, Jeroen D. C.
    van der Marel, Gijs A.
    Overkleeft, Herman S.
    Linthorst, Gabor E.
    Groener, Johanna E. M.
    Aerts, Johannes M.
    Poorthuis, Ben J. H. M.
    [J]. CLINICAL CHEMISTRY, 2013, 59 (03) : 547 - 556
  • [13] Newborn Screening for Fabry Disease in Taiwan Reveals a High Incidence of the Later-Onset GLA Mutation c.936+919G > A (IVS4+919G > A)
    Hwu, Wuh-Liang
    Chien, Yin-Hsiu
    Lee, Ni-Chung
    Chiang, Shu-Chuan
    Dobrovolny, Robert
    Huang, Ai-Chu
    Yeh, Hui-Ying
    Chao, May-Chin
    Lin, Shio-Jean
    Kitagawa, Teruo
    Desnick, Robert J.
    Hsu, Li-Wen
    [J]. HUMAN MUTATION, 2009, 30 (10) : 1397 - 1405
  • [14] Analysis of Lyso-Globotriaosylsphingosine in Dried Blood Spots
    Johnson, Britt
    Mascher, Hermann
    Mascher, Daniel
    Legnini, Elisa
    Hung, Christina Y.
    Dajnoki, Angela
    Chien, Yin-Hsiu
    Marodi, Laszlo
    Hwu, Wuh-Liang
    Bodamer, Olaf A.
    [J]. ANNALS OF LABORATORY MEDICINE, 2013, 33 (04) : 274 - 278
  • [15] Screening for Fabry disease in high-risk populations: a systematic review
    Linthorst, G. E.
    Bouwman, M. G.
    Wijburg, F. A.
    Aerts, J. M. F. G.
    Poorthuis, B. J. H. M.
    Hollak, C. E. M.
    [J]. JOURNAL OF MEDICAL GENETICS, 2010, 47 (04) : 217 - 222
  • [16] Globotriaosylsphingosine (lyso-Gb3) might not be a reliable marker for monitoring the long-term therapeutic outcomes of enzyme replacement therapy for late-onset Fabry patients with the Chinese hotspot mutation (IVS4+919G>A)
    Liu, Hao-Chuan
    Lin, Hsiang-Yu
    Yang, Chia-Feng
    Liao, Hsuan-Chieh
    Hsu, Ting-Rong
    Lo, Chiao-Wei
    Chang, Fu-Pang
    Huang, Chun-Kai
    Lu, Yung-Hsiu
    Lin, Shuan-Pei
    Yu, Wen-Chung
    Niu, Dau-Ming
    [J]. ORPHANET JOURNAL OF RARE DISEASES, 2014, 9
  • [17] A NOTE ON A GENERAL DEFINITION OF THE COEFFICIENT OF DETERMINATION
    NAGELKERKE, NJD
    [J]. BIOMETRIKA, 1991, 78 (03) : 691 - 692
  • [18] Fabry disease: Detection of undiagnosed hemodialysis patients and identification of a "renal variant" phenotype
    Nakao, S
    Kodama, C
    Takenaka, T
    Tanaka, A
    Yasumoto, Y
    Yoshida, A
    Kanzaki, T
    Enriquez, ALD
    Eng, CM
    Tanaka, H
    Tei, C
    Desnick, RJ
    [J]. KIDNEY INTERNATIONAL, 2003, 64 (03) : 801 - 807
  • [19] Nowak A, 2017, MOL GENET METAB, V120, P57, DOI 10.1016/j.ymgme.2016.10.006